EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Perihilar cholangiocarcinoma: Expanding the role of liver transplantation in the era of multimodal therapy

Jia-Yu Liu, Chuan-Jin Miao, Bin Mei, Xiao-Ping Chen, Zhi-Yong Huang, Bin-Yong Liang

European Journal of Surgical Oncology · 2026-09 · 52 (9) · 112003

DOI: 10.1016/j.ejso.2026.112003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Surgical Oncology, 2026-09. Verfasst von Jia-Yu Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 43…. Hauptthemen laut MEDLINE: Liver Transplantation, Bile Duct Neoplasms, Klatskin Tumor. Die Arbeit nennt 93 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Perihilar cholangiocarcinoma (pCCA) accounts for approximately 50% of all cholangiocarcinomas and carries a dismal prognosis owing to late diagnosis and high post-resection recurrence rates. Over the past two decades, liver transplantation (LT) following neoadjuvant therapy according to the Mayo Criteria has yielded acceptable long-term survival in highly selected patients with unresectable pCCA, establishing LT as an established treatment option. Nevertheless, substantial challenges remain, including tumor progression on the waiting list, intolerance to neoadjuvant therapy, and postoperative complications from prior chemoradiation. Moreover, pCCA recurrence is closely linked to post-transplant immunosuppressive management, and minimizing long-term immunosuppression may be critical. This review analytically examines the current role of LT for pCCA, emphasizing patient selection, standardized neoadjuvant regimens, immunological considerations, and favorable prognostic factors. The emerging potential and risks of incorporating immune checkpoint inhibitors in the pre-transplant setting are also explored. By synthesizing available evidence, we aim to define the clinical contexts in which LT may confer durable benefit and to highlight the key obstacles limiting its broader application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationBile Duct NeoplasmsKlatskin TumorHumansNeoadjuvant TherapyCombined Modality TherapyPatient SelectionPrognosisImmune Checkpoint InhibitorsImmunosuppressive AgentsNeoplasm Recurrence, Local

Stichwörter der Autor:innen

CholangiocarcinomaComplicationsImmunotherapyKlastinLiver transplantationNeoadjuvant therapy

Substanzen

Immune Checkpoint InhibitorsImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Department of Hepatobiliary and Pancreatic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. Electronic address: Binyong.liang@tjh.tjmu.edu.cn.

Zitieren

APA

Liu, J. Y., Miao, C. J., Mei, B., Chen, X. P., Huang, Z. Y., & Liang, B. Y. (2026). Perihilar cholangiocarcinoma: Expanding the role of liver transplantation in the era of multimodal therapy. European Journal of Surgical Oncology, 52(9), 112003. https://doi.org/10.1016/j.ejso.2026.112003

Vancouver

Liu JY, Miao CJ, Mei B, Chen XP, Huang ZY, Liang BY. Perihilar cholangiocarcinoma: Expanding the role of liver transplantation in the era of multimodal therapy. European Journal of Surgical Oncology. 2026;52(9):112003. doi:10.1016/j.ejso.2026.112003

BibTeX
@article{Liu2026,
  author = {Liu, Jia-Yu and Miao, Chuan-Jin and Mei, Bin and Chen, Xiao-Ping and Huang, Zhi-Yong and Liang, Bin-Yong},
  title = {Perihilar cholangiocarcinoma: Expanding the role of liver transplantation in the era of multimodal therapy},
  journal = {European Journal of Surgical Oncology},
  year = {2026},
  volume = {52},
  number = {9},
  pages = {112003},
  doi = {10.1016/j.ejso.2026.112003}
}
Kostenlos starten →